EP1383484B1 - Medicinal tablet with prolonged release of the active principle - Google Patents

Medicinal tablet with prolonged release of the active principle Download PDF

Info

Publication number
EP1383484B1
EP1383484B1 EP02726276A EP02726276A EP1383484B1 EP 1383484 B1 EP1383484 B1 EP 1383484B1 EP 02726276 A EP02726276 A EP 02726276A EP 02726276 A EP02726276 A EP 02726276A EP 1383484 B1 EP1383484 B1 EP 1383484B1
Authority
EP
European Patent Office
Prior art keywords
pastille
active principle
minutes
matrix agent
buccal cavity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02726276A
Other languages
German (de)
French (fr)
Other versions
EP1383484A1 (en
Inventor
Pierre Dupinay
Robert Torres
Christine Capon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to DK10154760.2T priority Critical patent/DK2184057T3/en
Priority to EP10182581A priority patent/EP2269588A1/en
Priority to EP10154760.2A priority patent/EP2184057B1/en
Publication of EP1383484A1 publication Critical patent/EP1383484A1/en
Application granted granted Critical
Publication of EP1383484B1 publication Critical patent/EP1383484B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the invention relates to medicinal sucking lozenges, of solid consistency for dissolving in the oral cavity, comprising a matrix agent slowing the release of the active ingredient in the buccopharyngeal sphere.
  • the invention also relates to a process for manufacturing such a pellet.
  • Medicinal lozenges are already known which are preparations based on sweetening substances, of solid consistency, intended to dissolve in the oral cavity.
  • They are generally in various forms: spheres, cylinders, squares or any other polygonal shape.
  • pellets also called cooked sugars
  • auxiliary substances such as sweeteners, antioxidants, dyes, flavors, and the active ingredient (s).
  • the active ingredient (s) are added to the mass in a mixer as well as the auxiliary substances.
  • the mass thus prepared is kneaded on a suitable cold surface, then rolled and spun, to then be pressed or cut into pellets to the desired shape.
  • the current medicinal pellets of cooked sugar dissolve very quickly in the mouth, between 5 and 10 minutes maximum, thus releasing too quickly the active ingredient (s) that they contain and which are immediately swallowed and absorbed at the level of the tract. digestive.
  • the present invention provides novel medicinal pellets of cooked sugar which make it possible to overcome this disadvantage of the prior art.
  • the invention relates, according to a first aspect, to a medicinal lozenge for sucking boiled sugar, of solid consistency, intended to dissolve in the oral cavity, comprising as active principle the nicotine, the tablet also comprising at least one matrix agent. to slow down the release of the active ingredient (s) which then remain in prolonged contact with the buccopharyngeal sphere.
  • the matrix agent is an agent capable of slowing the dissolution of the cooked sugar in the mouth.
  • the matrix agent also confers on the pellet an increased, durable resistance even in contact with the saliva so that the patient can not crunch the pellet and swallow pieces thereof.
  • the dissolution time in the oral cavity of the pellet is at least 15 minutes, and typically 25 to 35 minutes, preferably 30 minutes.
  • the matrix agent is typically chosen from the group consisting of cellulose derivatives, these substances being used alone or as a mixture and representing 1 to 10% by weight of the tablet, typically 1 to 5%.
  • the matrix agent is selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylcellulose.
  • the pellet further comprises a major sugar excipient, or diluent, consisting of the isomalt representing 80 to 99% by weight of the pellet.
  • the tablet further comprises at least one auxiliary substance chosen from sweeteners, antioxidants, dyes and flavors.
  • the invention relates to a tablet comprising nicotine as the active ingredient.
  • the tablet comprises isomalt, methocel® (hydroxypropylcellulose), nicotine and a sweetening agent with a high sweetening power, in particular aspartame.
  • the matrix agent makes it possible to slow the dissolution of the cooked sugar in the mouth and at the same time the release of the active ingredient (s) at the site of action.
  • the matrix agent confers on the cooked sugar pellet a significant resistance, durable even in contact with saliva, greater than that usually obtained on this type of preparation, so that it becomes impossible for the patient to chew on this lozenge and swallow the pieces.
  • This complementary phenomenon is particularly favorable to the prolonged effect sought on the site of action, since the patient is obliged to let the pellet melt in the mouth until it is completely dissolved.
  • the dissolving time in the oral cavity, obtained with this new form of cooked sugar pellets, can reach 30 minutes. This time can be modulated according to the choice of the sweetening agent (s) and the matrix agent (s).
  • hydroxypropylcellulose hydroxypropylmethylcellulose
  • hydroxyethylcellulose hydroxyethylcellulose
  • ethylcellulose hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose and ethylcellulose
  • Hydroxyethylcelluloses are for example described in " Handbook of Water-Soluble Gums and Resins, ed.R.L.Davidson, pub.McGraw-Hill (1980) ).
  • CMC carboxymethylcellulose
  • MC methylcellulose
  • EHEC ethylhydroxyethylcellulose
  • HEMC hydroxyethylmethylcellulose
  • HHEC modified hydroxyethylcellulose
  • HMEHEC modified ethylhydroxyethylcellulose
  • CMC carboxymethylcellulose
  • MC methylcellulose
  • EHEC ethylhydroxyethylcellulose
  • HEMC hydroxyethylmethylcellulose
  • HHEC modified hydroxyethylcellulose
  • HMEHEC modified ethylhydroxyethylcellulose
  • CMEHEC carboxymethylhydroxyethylcellulose
  • the substances constituting the matrix agent can be used alone or as a mixture. Their choices, their concentrations will depend on the sugar or substances used, the active ingredient retained and their activity, the desired time of dissolution in the mouth and the texture of the cooked sugar.
  • the major sugar excipient, or diluent, is isomalt.
  • Auxiliary substances are those usually used: sweeteners, antioxidants, dyes, flavors ....
  • the manufacturing method according to the invention comprises four steps: a boiling step, a cooking step, a mixing step, a step of manufacturing the cooked sugar lozenges.
  • the manufacturing process is in line with current pharmaceutical requirements.
  • the active ingredient is nicotine.
  • the matrix agent may be incorporated either during the boiling step or during the cooking step, or during mixing.
  • the choice of the step of incorporation of the matrix agent will depend on the final characteristics of the desired cooked sugar pellets.
  • the pellets thus obtained are very different from other galenic forms such as tablets which may contain some of the non-cellulosic polysaccharides and cellulose derivatives mentioned above.
  • pellet dosage form is very specific, having been the subject of a monograph in the French Pharmacopoeia Xth Edition (July 1987).
  • Pellets are solid-consistency saccharoids intended to slowly disintegrate in the oral cavity. They are in particular in a hemispherical form and generally weigh between 1 g and 3 g. They are generally composed of sucrose in a high proportion, a clumping substance such as gum arabic or gum tragacanth, one or more active ingredients and possibly auxiliary substances (dyes, flavoring ).
  • the pellets are prepared by first making a paste with a portion of sucrose. This dough is heated until slightly boiling. The rest of the sucrose, the active ingredient (s) and the auxiliary substances are then added. After homogenization the mass thus prepared is dropped dropwise on a cold plate or injected into a suitable mold.
  • Amylin hydrochloride 2,000 mg Cetylpyridinium hydrochloride 1,000 mg polyvinylpyrrolidone 100,000 mg Sucrose 1577,000 mg Glucose 820,000 mg Aroma QS Dye QS Water QS
  • Dextromethorphan hydrobromide 20,000 mg Citric acid 37,000 mg polymethyl 50,000 mg Sucrose 1,255,000 mg Glucose 1 111,000 mg Aroma QS Water QS
  • the tablet of Examples 8 and 9 comprises 2.1303 g of nicotine.
  • the manufacture of these pellets is carried out hot.
  • the matrix agent is incorporated in the sweetening base at a temperature of the order of 70 to 95 ° C (boiling step), preferably at 90 ° C.
  • the assembly is then heated to about 130 ° C at the time of cooking.
  • the nicotine is then added (mixing step) in the mass at a temperature of the order of 110 to 130 ° C, preferably 120 ° C.
  • Nicotine Polacrilex is a C 10 H 14 N 2 nicotine complex with an ion exchange resin (catioresin carboxylate); this complex has the formula: C 10 H 14 N 2 (C 18 H 22 O 4 ) n

Abstract

A suckable, solid medicinal pastille (P), which is made from boiled sugar, dissolves in the buccal cavity and contains active agent(s) (A), and additionally a matrix component (I) for retarding the release of (A), such that (A) remains in contact with the mouth/pharynx region for a prolonged period and the dissolution time in the buccal cavity is more than 15 minutes. An independent claim is also included for the production of the (P).

Description

L'invention concerne des pastilles médicamenteuses à sucer, de consistance solide destinées à se dissoudre dans la cavité buccale, comprenant un agent matriciel ralentissant la libération du principe actif dans la sphère buccopharyngée. L'invention concerne également un procès de fabrication d'une telle pastille.The invention relates to medicinal sucking lozenges, of solid consistency for dissolving in the oral cavity, comprising a matrix agent slowing the release of the active ingredient in the buccopharyngeal sphere. The invention also relates to a process for manufacturing such a pellet.

On connaît déjà des pastilles à sucer médicamenteuses qui sont des préparations à base de substances sucrantes, de consistance solide, destinées à se dissoudre dans la cavité buccale.Medicinal lozenges are already known which are preparations based on sweetening substances, of solid consistency, intended to dissolve in the oral cavity.

Elles se présentent généralement sous des formes variées : sphères, cylindres, carrés ou toute autre forme polygonale.They are generally in various forms: spheres, cylinders, squares or any other polygonal shape.

Ces pastilles encore appelées sucres cuits sont préparées à partir d'un sirop de substance diluante sucrée porté à ébullition, puis cuit à une température plus élevée, typiquement de 100°C à 160°C. A cette base sucrée sont ajoutées des substances auxiliaires telles qu'édulcorants, antioxydants, colorants, arômes, et le ou les principes actifs.These pellets, also called cooked sugars, are prepared from a syrup of sweetened diluent substance boiled and then baked at a higher temperature, typically 100 ° C to 160 ° C. To this sweet base are added auxiliary substances such as sweeteners, antioxidants, dyes, flavors, and the active ingredient (s).

En fin de cuisson le ou les principes actifs sont ajoutés à la masse dans un mélangeur ainsi que les substances auxiliaires.At the end of cooking, the active ingredient (s) are added to the mass in a mixer as well as the auxiliary substances.

La masse ainsi préparée est pétrie sur une surface froide appropriée, puis roulée et filée, pour être ensuite pressée ou découpée en pastilles à la forme désirée.The mass thus prepared is kneaded on a suitable cold surface, then rolled and spun, to then be pressed or cut into pellets to the desired shape.

Ces pastilles à sucer médicamenteuses de sucre cuit sont essentiellement destinées, du fait de leur lieu de dissolution, aux traitements locaux de la sphère buccale et oropharyngienne mais aussi aux principes actifs absorbés par voie perlinguale.These medicinal sucking lozenges of cooked sugar are essentially intended, because of their place of dissolution, to the local treatments of the oral and oropharyngeal spheres but also to the active principles absorbed perlingually.

De ce fait il est nécessaire que les principes actifs choisis pour ces modes d'action se libèrent progressivement pour rester au contact de la sphère buccopharyngée le plus longtemps possible, tout en évitant un passage rapide et massif dans le tractus digestif, ce qui aurait pour conséquence de les rendre inefficaces sur le lieu d'application ou la voie d'absorption choisis.Therefore it is necessary that the active principles chosen for these modes of action are gradually released to stay in contact with the buccopharyngeal sphere for as long as possible, while avoiding a rapid and massive passage in the digestive tract, which would have consequence of rendering them ineffective at the place of application or the chosen route of absorption.

Or, les pastilles médicamenteuses de sucre cuit actuelles se dissolvent très rapidement en bouche, entre 5 et 10 minutes maximum, libérant ainsi trop vite le ou les principes actifs qu'elles contiennent et qui de ce fait sont aussitôt déglutis et absorbés au niveau du tractus digestif.Now, the current medicinal pellets of cooked sugar dissolve very quickly in the mouth, between 5 and 10 minutes maximum, thus releasing too quickly the active ingredient (s) that they contain and which are immediately swallowed and absorbed at the level of the tract. digestive.

La présente invention propose de nouvelles pastilles médicamenteuses de sucre cuit qui permettent de pallier cet inconvénient de l'art antérieur.The present invention provides novel medicinal pellets of cooked sugar which make it possible to overcome this disadvantage of the prior art.

A cet effet l'invention concerne selon un premier aspect une pastille médicamenteuse à sucer de sucre cuit, de consistance solide, destinée à se dissoudre dans la cavité buccale, comprenant comme principe actif la nicotine, la pastille comprenant en outre au moins un agent matriciel permettant de ralentir la libération du ou des principes actifs qui restent alors au contact prolongé de la sphère buccopharyngée.To this end, the invention relates, according to a first aspect, to a medicinal lozenge for sucking boiled sugar, of solid consistency, intended to dissolve in the oral cavity, comprising as active principle the nicotine, the tablet also comprising at least one matrix agent. to slow down the release of the active ingredient (s) which then remain in prolonged contact with the buccopharyngeal sphere.

L'agent matriciel est un agent apte à ralentir la dissolution du sucre cuit en bouche.The matrix agent is an agent capable of slowing the dissolution of the cooked sugar in the mouth.

Selon un mode de réalisation, l'agent matriciel confère en outre à la pastille une résistance accrue, durable même au contact de la salive de sorte que le patient ne peut croquer cette pastille et en avaler des morceaux.According to one embodiment, the matrix agent also confers on the pellet an increased, durable resistance even in contact with the saliva so that the patient can not crunch the pellet and swallow pieces thereof.

Le temps de dissolution dans la cavité buccale de la pastille est d'au moins 15 minutes, et typiquement de 25 à 35 minutes, de préférence 30 minutes.The dissolution time in the oral cavity of the pellet is at least 15 minutes, and typically 25 to 35 minutes, preferably 30 minutes.

L'agent matriciel est typiquement choisi dans le groupe constitué par les dérivés cellulosiques, ces substances étant utilisées seules ou en mélange et représentant 1 à 10% en poids de la pastille, typiquement 1 à 5%.The matrix agent is typically chosen from the group consisting of cellulose derivatives, these substances being used alone or as a mixture and representing 1 to 10% by weight of the tablet, typically 1 to 5%.

Selon une réalisation, l'agent matriciel est choisi dans le groupe constitué par l'hydroxypropylcellulose, l'hydroxypropylméthylcellulose, l'hydroxyéthylcellulose, l'éthyllcellulose.In one embodiment, the matrix agent is selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylcellulose.

La pastille comprend en outre un excipient sucré majeur, ou diluant, constitué par l'isomalt représentant 80 à 99% en poids de la pastille.The pellet further comprises a major sugar excipient, or diluent, consisting of the isomalt representing 80 to 99% by weight of the pellet.

Selon une réalisation, la pastille comprend en outre au moins une substance auxiliaire choisie parmi les édulcorants, les antioxydants, les colorants, les arômes.In one embodiment, the tablet further comprises at least one auxiliary substance chosen from sweeteners, antioxidants, dyes and flavors.

Selon une réalisation préférée, l'invention concerne une pastille comprenant comme principeactif la nicotine.According to a preferred embodiment, the invention relates to a tablet comprising nicotine as the active ingredient.

Selon une réalisation préférée, la pastille comprend de l'isomalt, du méthocel® (hydroxypropylcellulose), de la nicotine et un agent sucrant à fort pouvoir sucrant, notamment de l'aspartam.In a preferred embodiment, the tablet comprises isomalt, methocel® (hydroxypropylcellulose), nicotine and a sweetening agent with a high sweetening power, in particular aspartame.

Selon un autre aspect l'invention a pour objet un procédé de fabrication d'une pastille médicamenteuse décrite précédemment, comprenant successivement :

  • une étape d'ébullition d'un sirop de substance diluante sucrée;
  • une étape de cuisson à une température plus élevée, de l'ordre de 100°C à 160°C;
  • une étape de mélange avec incorporation du ou des principes actifs et de la ou des substances auxiliaires;
  • une étape de fabrication de la pastille de sucre suit ;
l'agent matriciel étant incorporé soit au cours de l'étape d'ébullition, soit au cours de l'étape de cuisson, soit lors du mélange.According to another aspect, the subject of the invention is a method for manufacturing a medicinal pellet described above, comprising successively:
  • a boiling step of a syrup of sweet diluent substance;
  • a firing step at a higher temperature, of the order of 100 ° C to 160 ° C;
  • a mixing step with incorporation of the active ingredient (s) and the auxiliary substance (s);
  • a step of manufacturing the sugar pellet follows;
the matrix agent being incorporated either during the boiling step, during the cooking step, or during mixing.

D'autres aspects et avantages de l'invention apparaîtront lors de la description détaillée qui suit.Other aspects and advantages of the invention will become apparent from the detailed description which follows.

L'agent matriciel permet de ralentir la dissolution du sucre cuit en bouche et par la même la libération du ou des principes actifs sur le site d'action.The matrix agent makes it possible to slow the dissolution of the cooked sugar in the mouth and at the same time the release of the active ingredient (s) at the site of action.

Par ailleurs fait inattendu, contrairement à ce que l'on aurait pu penser, l'agent matriciel confère à la pastille de sucre cuit une résistance importante, durable même au contact de la salive, supérieure à celle habituellement obtenue sur ce type de préparation, de sorte qu'il devient impossible au patient de croquer cette pastille et d'en avaler les morceaux.Moreover, unexpectedly, contrary to what one might have thought, the matrix agent confers on the cooked sugar pellet a significant resistance, durable even in contact with saliva, greater than that usually obtained on this type of preparation, so that it becomes impossible for the patient to chew on this lozenge and swallow the pieces.

Ce phénomène complémentaire est particulièrement favorable à l'effet prolongé recherché sur le site d'action, puisque le patient se trouve dans l'obligation de laisser fondre la pastille en bouche jusqu'à sa complète dissolution.This complementary phenomenon is particularly favorable to the prolonged effect sought on the site of action, since the patient is obliged to let the pellet melt in the mouth until it is completely dissolved.

Le temps de dissolution dans la cavité buccale, obtenu avec cette nouvelle forme de pastilles de sucre cuit, peut atteindre 30 minutes. Ce temps peut être modulé en fonction du choix du ou des agents sucrants et du ou des agents matriciels.The dissolving time in the oral cavity, obtained with this new form of cooked sugar pellets, can reach 30 minutes. This time can be modulated according to the choice of the sweetening agent (s) and the matrix agent (s).

Ces nouvelles pastilles de sucre cuit peuvent présenter toutes les formes géométriques habituelles déjà citées auparavant.These new pellets of cooked sugar can present all the usual geometric shapes already mentioned before.

Elles sont composées en forte proportion d'une substance diluante sucrée ou excipient constituant la base de la préparation, qui est l'Isomalt.They are composed in high proportion of a sweet diluent substance or excipient constituting the base of the preparation, which is Isomalt.

Parmi les dérivés cellulosiques utilisables, on préférera les dérivés : hydroxypropylcellulose, hydroxypropylméthylcellulose, hydroxyéthylcellulose, éthylcellulose. Les hydroxy-éthylcelluloses sont par exemple décrites dans " Handbook of water-soluble gums and resins" , ed.R .L.Davidson, pub.McGraw-Hill (1980 ). On pourra aussi utiliser notamment les dérivés : carboxyméthylcellulose (CMC), méthylcellulose (MC), éthylhydroxyéthylcellulose (EHEC), hydroxyéthylméthylcellulosè (HEMC), hydroxyéthylcellulose modifié (HMHEC), éthylhydroxyéthylcellulose modifié (HMEHEC), carboxyméthylhydroxyéthylcellulose (CMHEC).Among the cellulose derivatives which may be used, the derivatives: hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose and ethylcellulose will be preferred. Hydroxyethylcelluloses are for example described in " Handbook of Water-Soluble Gums and Resins, ed.R.L.Davidson, pub.McGraw-Hill (1980) ). It is also possible to use the derivatives: carboxymethylcellulose (CMC), methylcellulose (MC), ethylhydroxyethylcellulose (EHEC), hydroxyethylmethylcellulose (HEMC), modified hydroxyethylcellulose (HMHEC), modified ethylhydroxyethylcellulose (HMEHEC), carboxymethylhydroxyethylcellulose (CMHEC).

Les substances constituant l'agent matriciel peuvent être utilisées seules ou en mélange. Leurs choix, leurs concentrations seront fonction de la ou des substances sucrantes utilisées, du principe actif retenus et de leur activité, du temps de dissolution en bouche et de la texture du sucre cuit souhaités.The substances constituting the matrix agent can be used alone or as a mixture. Their choices, their concentrations will depend on the sugar or substances used, the active ingredient retained and their activity, the desired time of dissolution in the mouth and the texture of the cooked sugar.

L'excipient sucré majeur, ou diluant, est constitué par l'isomalt.The major sugar excipient, or diluent, is isomalt.

Les substances auxiliaires sont celles habituellement mises en oeuvre : édulcorants, antioxydants, colorants, arômes....Auxiliary substances are those usually used: sweeteners, antioxidants, dyes, flavors ....

Le procédé de fabrication selon l'invention comprend quatre étapes : une étape d'ébullition, une étape de cuisson, une étape de mélange, une étape de fabrication des pastilles de sucre cuit.The manufacturing method according to the invention comprises four steps: a boiling step, a cooking step, a mixing step, a step of manufacturing the cooked sugar lozenges.

Le procédé de fabrication est conforme aux exigences pharmaceutiques actuelles. Le principe actif est la nicotine.The manufacturing process is in line with current pharmaceutical requirements. The active ingredient is nicotine.

L'agent matriciel peut être incorporé soit au cours de l'étape d'ébullition, soit au cours de l'étape de cuisson, soit lors du mélange.The matrix agent may be incorporated either during the boiling step or during the cooking step, or during mixing.

Le choix de l'étape d'incorporation de l'agent matriciel sera fonction des caractéristiques finales des pastilles de sucre cuit souhaitées.The choice of the step of incorporation of the matrix agent will depend on the final characteristics of the desired cooked sugar pellets.

Les pastilles ainsi obtenues sont très différentes d'autres formes galéniques telles que des comprimés susceptibles de contenir certains des polysaccharides non cellulosiques et des dérivés cellulosiques cités précédemment.The pellets thus obtained are very different from other galenic forms such as tablets which may contain some of the non-cellulosic polysaccharides and cellulose derivatives mentioned above.

En effet, la forme galénique pastille est bien spécifique, ayant fait l'objet d'une monographie à la Pharmacopée Française Xème Edition (juillet 1987). Les pastilles sont des saccharoïdes de consistance solide destinées à se désagréger lentement dans la cavité buccale. Elles se présentent notamment sous une forme hémisphérique et pèsent généralement entre et 1 g et 3 g. Elles sont généralement composées de saccharose en forte proportion, d'une substance agglomérante telle que gomme arabique ou gomme adragante, d'un ou plusieurs principes actifs et éventuellement de substances auxiliaires (colorants, aromatisants ...). Les pastilles sont préparées en réalisant d'abord une pâte avec une partie de saccharose. Cette pâte est chauffée jusqu'à légère ébullition. Le reste du saccharose, le ou les principes actifs ainsi que les substances auxiliaires sont alors ajoutés. Après homogénéisation on fait tomber la masse ainsi préparée goutte à goutte sur une plaque froide ou on l'injecte dans un moule approprié.Indeed, the pellet dosage form is very specific, having been the subject of a monograph in the French Pharmacopoeia Xth Edition (July 1987). Pellets are solid-consistency saccharoids intended to slowly disintegrate in the oral cavity. They are in particular in a hemispherical form and generally weigh between 1 g and 3 g. They are generally composed of sucrose in a high proportion, a clumping substance such as gum arabic or gum tragacanth, one or more active ingredients and possibly auxiliary substances (dyes, flavoring ...). The pellets are prepared by first making a paste with a portion of sucrose. This dough is heated until slightly boiling. The rest of the sucrose, the active ingredient (s) and the auxiliary substances are then added. After homogenization the mass thus prepared is dropped dropwise on a cold plate or injected into a suitable mold.

Ainsi la pastille diffère nettement de comprimés :

  • par son mode d'utilisation
  • par sa composition, et notamment l'excipient utilisé (isomalt) et sa concentration élevée de l'ordre de 80 à 99% de la formule
  • par son mode de préparation spécifique, totalement différent des comprimés, et nécessitant un appareillage spécifique :
    • o cuisson du mélange sous vide d'où le terme de « sucre cuit »
    • o mélange et refroidissement de la pâte obtenue sur une table froide munie d'un pétrisseur
    • o extrusion de la masse
    • o pressage sur presse totalement différente d'une comprimeuse En particulier le pourcentage d'agent matriciel dans la pastille est faible, de l'ordre de 1 à 10%, de préférence de 1 à 5%.
Thus the lozenge clearly differs from tablets:
  • by its mode of use
  • by its composition, and in particular the excipient used (isomalt) and its high concentration of the order of 80 to 99% of the formula
  • by its specific method of preparation, totally different from tablets, and requiring specific equipment:
    • o cooking the mixture under vacuum, hence the term "cooked sugar"
    • o mixing and cooling of the dough obtained on a cold table equipped with a kneader
    • o mass extrusion
    • In particular, the percentage of matrix agent in the tablet is small, of the order of 1 to 10%, preferably 1 to 5%.

On présente ci-après quelques exemples de pastilles selon l'invention.Some examples of pellets according to the invention are presented below.

Exemple 1 À titre de référence seulement Example 1 For reference only

Digluconate de chlorhexidineChlorhexidine digluconate 3,000 mg3,000 mg Tetracaïne chlorhydrateTetracaine hydrochloride 0,200 mg0.200 mg Acide ascorbiqueAscorbic acid 52,500 mg52,500 mg Hydroxypropyl methylcelluloseHydroxypropyl methylcellulose 100,000 mg100,000 mg Isomaltisomalt 2 317,1875 mg2,317.1755 mg Glycyrrhizinate d'ammoniumAmmonium glycyrrhizinate 5,000 mg5,000 mg Aspartamaspartame 1,000 mg1,000 mg ArômeAroma QSQS EauWater QSQS

Exemple 2 À titre de référence seulement Example 2 For reference only

Digluconate de chlorhexidineChlorhexidine digluconate 3,000 mg3,000 mg Acide ascorbiqueAscorbic acid 52,500 mg52,500 mg Hydroxypropyl methylcelluloseHydroxypropyl methylcellulose 50,000 mg50,000 mg Maltitolmaltitol 2 425,000 mg2,425,000 mg ErythrosineErythrosine 0,250 mg0.250 mg Arômesaromas QSQS EauWater QSQS

Exemple 3 À titre de référence seulement Example 3 For reference only

Cetylpyridiniumcetylpyridinium 2,500 mg2,500 mg Benzocaïnebenzocaine 2,000 mg2,000 mg Vitamine CVitamin C 52,500 mg52,500 mg Hydroxypropyl methylcelluloseHydroxypropyl methylcellulose 100,000 mg100,000 mg Isomaltisomalt 2 425,000 mg2,425,000 mg Arômesaromas QSQS EauWater QSQS

Exempte 4 À titre de référence seulement Exempt 4 For reference only

Extrait d'erysimumErysimum extract 15,000 mg15,000 mg Carraghenatecarrageenan 100,000 mg100,000 mg SaccharoseSucrose 1 471,250 mg1,471.250 mg GlucoseGlucose 1 000,000 mg1,000,000 mg Glycyrrhizinate d'ammoniumAmmonium glycyrrhizinate 1,000 mg1,000 mg ArômeAroma QSQS EauWater QSQS

Exemple 5 À titre de référence seulement Example 5 For reference only

NicotineNicotine 1,000 ou 2,000 mg1,000 or 2,000 mg Hydroxypropyl methylcelluloseHydroxypropyl methylcellulose 100,000 mg100,000 mg Cyclodextrinecyclodextrin 50,000 mg50,000 mg Isomaltisomalt 2 306,083 mg2,306,083 mg Aspartamaspartame 0,750 mg0.750 mg ArômeAroma QSQS EauWater QSQS

Exemple 6 À titre de référence seulement Example 6 For reference only

Chlorhydrate d'amyleïneAmylin hydrochloride 2,000 mg2,000 mg Chlorhydrate de cetylpyridiniumCetylpyridinium hydrochloride 1,000 mg1,000 mg Polyvinylpyrrolidonepolyvinylpyrrolidone 100,000 mg100,000 mg SaccharoseSucrose 1577,000 mg1577,000 mg GlucoseGlucose 820,000 mg820,000 mg ArômeAroma QSQS ColorantDye QSQS EauWater QSQS

Exemple 7 À titre de référence seulement Example 7 For reference only

Dextromethorphane bromhydrateDextromethorphan hydrobromide 20,000 mg20,000 mg Acide citriqueCitric acid 37,000 mg37,000 mg Polyméthacrylatepolymethyl 50,000 mg50,000 mg SaccharoseSucrose 1 256,000 mg1,255,000 mg GlucoseGlucose 1 111,000 mg1 111,000 mg ArômeAroma QSQS EauWater QSQS

Exemple 8Example 8

Formule unitaireUnitary formula Matières PremièresRaw materials QuantitéQuantity Isomalt Type MIsomalt Type M 2350,10 mg2350.10 mg Methocel K 15 MMethocel K 15 M 100,00100.00 Nicotine Polacrilex titré 18%Nicotine Polacrilex titrated 18% 11,83511.835 Aspartamaspartame 0,750 -0.750 - Acesulfam KAcesulfam K 1,2501,250 Arôme Peppermint 13-571-016Peppermint aroma 13-571-016 16,0016,00 Arôme Peppermint 13-627-517Peppermint aroma 13-627-517 20,0020.00 TotalTotal 2500 mg2500 mg

Exemple 9Example 9

Formule unitaireUnitary formula Matières PremièresRaw materials QuantitéQuantity Isomalt Type MIsomalt Type M 2338,76 mg2338.76 mg Methocel K 15 MMethocel K 15 M 100,00100.00 Nicotine Polacrilex titré 18%Nicotine Polacrilex titrated 18% 11,83511.835 Aspartamaspartame 0,9000,900 Acesulfam KAcesulfam K 1,5001,500 Arôme Peppermint 13-571-016Peppermint aroma 13-571-016 8,008.00 Extrait sec de réglisse déglycyrrhizinéDry deglycyrrhizine licorice extract 37,5037.50 Glycyrrhizinate d'ammoniumAmmonium glycyrrhizinate 1,5001,500 TotalTotal 2500 mg2500 mg

Ainsi, la pastille des exemples 8 et 9 comprend 2,1303 g de nicotine.Thus, the tablet of Examples 8 and 9 comprises 2.1303 g of nicotine.

La fabrication de ces pastilles est réalisée à chaud. L'agent matriciel est incorporé dans la base sucrante à une température de l'ordre de 70 à 95°C (étape d'ébullition), de préférence à 90°C. L'ensemble est ensuite chauffé à environ 130°C au moment de la cuisson. La nicotine est alors ajoutée (étape du mélange) dans la masse à une température de l'ordre de 110 à 130°C, de préférence 120°C.The manufacture of these pellets is carried out hot. The matrix agent is incorporated in the sweetening base at a temperature of the order of 70 to 95 ° C (boiling step), preferably at 90 ° C. The assembly is then heated to about 130 ° C at the time of cooking. The nicotine is then added (mixing step) in the mass at a temperature of the order of 110 to 130 ° C, preferably 120 ° C.

La nicotine Polacrilex est un complexe de nicotine C10H14N2 avec une résine échangeuse d'ions (catiorésine carboxylate); ce complexe à pour formule :C10H14N2(C18H22O4)n Nicotine Polacrilex is a C 10 H 14 N 2 nicotine complex with an ion exchange resin (catioresin carboxylate); this complex has the formula: C 10 H 14 N 2 (C 18 H 22 O 4 ) n

Claims (6)

  1. Medicinal cooked sugar pastille to be sucked, of solid consistency, intended to dissolve in the buccal cavity, comprising:
    • nicotine as active principal;
    • a major sweet excipient or diluent formed by isomalt representing 80 to 99% by weight of the pastille, and
    • a cellulosic-type matrix agent representing from 1 to 10% by weight of the pastille and allowing increased resistance of said pastille and thus allowing the release of said active principle to be slowed, which active principle remains in prolonged contact with the buccopharyngeal area, the time of dissolution of the pastille in the buccal cavity being at least 15 minutes.
  2. Pastille according to Claim 1, characterized in that the cellulosic-type matrix agent is chosen from the group formed by hydroxypropylcellulose, hydroxy-ethylcellulose, ethylcellulose and in particular hydroxypropylmethylcellulose.
  3. Pastille according to any one of the preceding claims, characterized in that it further comprises at least one auxiliary substance chosen from sweeteners, antioxidants, coloring agents and flavors.
  4. Pastille according to any one of the preceding claims, characterized in that it comprises isomalt, Methocel® (hydroxypropylcellulose), nicotine and advantageously aspartame.
  5. Pastille according to any one of the preceding claims, characterized in that the time of dissolution of the pastille in the buccal cavity is from 25 to 35 minutes, preferably 30 minutes.
  6. Process for the production of a medicinal pastille according to any one of Claims 1 to 5, characterized in that it comprises successively:
    - a boiling step of a syrup of sugary diluent substance;
    - a cooking step at a higher temperature, in the order of 100°C to 160°C;
    - a mixing step with incorporation of the active principle and of the auxiliary substance(s);
    - a production step of the pastille;
    the matrix agent being incorporated either in the the course of the boiling step, or in the course of the cooking step, or during mixing.
EP02726276A 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active principle Expired - Lifetime EP1383484B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DK10154760.2T DK2184057T3 (en) 2001-04-25 2002-04-25 Long-acting active drug release tablet
EP10182581A EP2269588A1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active agent
EP10154760.2A EP2184057B1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0105554 2001-04-25
FR0105554A FR2823974B1 (en) 2001-04-25 2001-04-25 SLOW RELEASE MEDICINAL LABEL FOR THE ACTIVE INGREDIENT
PCT/FR2002/001421 WO2002085334A1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active principle

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10154760.2A Division EP2184057B1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active agent
EP10154760.2 Division-Into 2010-02-26

Publications (2)

Publication Number Publication Date
EP1383484A1 EP1383484A1 (en) 2004-01-28
EP1383484B1 true EP1383484B1 (en) 2010-04-28

Family

ID=8862665

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10154760.2A Expired - Lifetime EP2184057B1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active agent
EP10182581A Withdrawn EP2269588A1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active agent
EP02726276A Expired - Lifetime EP1383484B1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active principle

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP10154760.2A Expired - Lifetime EP2184057B1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active agent
EP10182581A Withdrawn EP2269588A1 (en) 2001-04-25 2002-04-25 Medicinal tablet with prolonged release of the active agent

Country Status (12)

Country Link
US (1) US8545870B2 (en)
EP (3) EP2184057B1 (en)
AT (1) ATE465721T1 (en)
BR (1) BRPI0209221B8 (en)
CA (1) CA2445200C (en)
CY (1) CY1117370T1 (en)
DE (1) DE60236149D1 (en)
DK (2) DK2184057T3 (en)
ES (2) ES2565464T3 (en)
FR (1) FR2823974B1 (en)
PT (1) PT1383484E (en)
WO (1) WO2002085334A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
SE0302947D0 (en) 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
UA112974C2 (en) * 2010-09-16 2016-11-25 Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид NICOTINE COMPOSITION (OPTIONS)
FR2978916B1 (en) * 2011-08-10 2013-07-26 Servier Lab SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) * 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US20130206150A1 (en) * 2012-02-10 2013-08-15 R.J. Reynolds Tobacco Company Multi-layer smokeless tobacco composition
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
FR2993778B1 (en) 2012-07-30 2016-06-17 Pf Medicament MULTIPLE KINETIC DELUXES FOR RELEASE OF ACTIVE INGREDIENTS
US9351936B2 (en) * 2013-10-03 2016-05-31 Altria Client Services Llc Nicotine lozenge
US11779045B2 (en) 2013-10-03 2023-10-10 Altria Client Services Llc Dissolvable-chewable exhausted-tobacco tablet
US9999243B2 (en) 2013-10-03 2018-06-19 Altria Client Services Llc Exhausted tobacco lozenge
US10244786B2 (en) 2013-10-03 2019-04-02 Altria Client Services Llc Tobacco lozenge
US10105320B2 (en) 2013-10-03 2018-10-23 Altria Client Services Soluble fiber lozenge
US9375033B2 (en) 2014-02-14 2016-06-28 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
CN108684938A (en) * 2018-04-16 2018-10-23 广州智特奇生物科技股份有限公司 A kind of plants essential oil coating buffer, microcapsules plants essential oil and preparation method thereof
US11672862B2 (en) 2019-12-09 2023-06-13 Nicoventures Trading Limited Oral products with reduced irritation
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
US11883527B2 (en) 2019-12-09 2024-01-30 Nicoventures Trading Limited Oral composition and method of manufacture
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11889856B2 (en) 2019-12-09 2024-02-06 Nicoventures Trading Limited Oral foam composition
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1144915A (en) * 1966-11-24 1969-03-12 Armour Pharma Improvements in or relating to pastille formulations
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8518927D0 (en) * 1985-07-26 1985-09-04 Vincent Processes Ltd Tablets
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
DE19536394A1 (en) * 1995-09-29 1997-04-03 Basf Ag Solid pharmaceutical forms, obtainable by extrusion of a polymer-active substance melt containing isomalt
DE19606968C2 (en) * 1996-02-24 1998-07-09 Suedzucker Ag Use of 1,1-GPS in hard caramels
CZ298212B6 (en) * 1996-05-13 2007-07-25 Novartis Consumer Health S. A. Slowly erodible lozenge
HRP970485A2 (en) * 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
IT1297233B1 (en) * 1996-10-29 1999-08-09 Montefarmaco Spa SOLID PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CANDIES CONTAINING DISINFECTANTS AND MUCO-ADHESIVE SUBSTANCES FOR TOPICAL DISINFECTION
US5942244A (en) * 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
US20040101543A1 (en) * 2002-03-22 2004-05-27 John Liu Nicotine-containing oral dosage form

Also Published As

Publication number Publication date
EP2184057B1 (en) 2016-01-13
FR2823974A1 (en) 2002-10-31
EP2184057A1 (en) 2010-05-12
ES2340761T3 (en) 2010-06-09
CY1117370T1 (en) 2017-04-26
FR2823974B1 (en) 2004-10-15
ATE465721T1 (en) 2010-05-15
CA2445200A1 (en) 2002-10-31
BRPI0209221B1 (en) 2018-03-13
BRPI0209221B8 (en) 2021-07-27
EP2269588A1 (en) 2011-01-05
PT1383484E (en) 2010-05-27
DK2184057T3 (en) 2016-04-18
US20060171994A1 (en) 2006-08-03
BR0209221A (en) 2004-06-15
DK1383484T3 (en) 2010-06-07
DE60236149D1 (en) 2010-06-10
EP1383484A1 (en) 2004-01-28
ES2565464T3 (en) 2016-04-04
US8545870B2 (en) 2013-10-01
CA2445200C (en) 2011-09-06
WO2002085334A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
EP1383484B1 (en) Medicinal tablet with prolonged release of the active principle
EP0542824B1 (en) Method for preparing a bioadhesive galenical and galenical thereby obtained
KR101699321B1 (en) Sublingual and Buccal Film Compositions
US4971798A (en) Hard confections containing hydrogenated isomaltulose and medicinally active ingredient
EP2317973B1 (en) Appetising medicament for oral administration in solid form
EP0814789B1 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
CA2017360A1 (en) Porous pharmaceutical form and preparation thereof
EP2131823B9 (en) Rapid-disintegration monolayer film for the oral administration of active substances
EP1165094B1 (en) Dispersible macrolide compounds and method for the production thereof
US20060263414A1 (en) Confectionery products for the treatment of dry mouth
WO2004032942A1 (en) Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin
US20110028480A1 (en) Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors
EP2879663B1 (en) Lozenges with multiple release kinetics for active ingredients
JP2016510799A (en) Encapsulated composition for binding aldehydes in the stomach
EP3560490A1 (en) Oral ibuprofen preparation
FR2666227A1 (en) Therapeutic composition, in particular for the treatment of complaints of the buccal cavity
CN117838668A (en) Donepezil hydrochloride oral instant film and preparation process thereof
FR2618678A1 (en) Pharmaceutical composition for the treatment of inflammations of the buccal cavity
FR2507084A1 (en) ANTIBIOTIC COMPOSITION FOR THE ADMINISTRATION OF PHOSPHOMYCIN IN THE FORM OF SLOWLY DISSOLVING TABLETS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PIERRE FABRE MEDICAMENT

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI & CIE SA

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100520

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2340761

Country of ref document: ES

Kind code of ref document: T3

REF Corresponds to:

Ref document number: 60236149

Country of ref document: DE

Date of ref document: 20100610

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100401312

Country of ref document: GR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100428

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110425

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20210316

Year of fee payment: 20

Ref country code: NL

Payment date: 20210312

Year of fee payment: 20

Ref country code: FI

Payment date: 20210322

Year of fee payment: 20

Ref country code: IE

Payment date: 20210322

Year of fee payment: 20

Ref country code: GR

Payment date: 20210318

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20210329

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20210429

Year of fee payment: 20

Ref country code: DE

Payment date: 20210408

Year of fee payment: 20

Ref country code: IT

Payment date: 20210412

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20210414

Year of fee payment: 20

Ref country code: AT

Payment date: 20210322

Year of fee payment: 20

Ref country code: BE

Payment date: 20210421

Year of fee payment: 20

Ref country code: SE

Payment date: 20210414

Year of fee payment: 20

Ref country code: GB

Payment date: 20210415

Year of fee payment: 20

Ref country code: CH

Payment date: 20210426

Year of fee payment: 20

Ref country code: ES

Payment date: 20210506

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60236149

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20220424

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20220425

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20220425

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20220424

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 465721

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220425

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220504

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220425

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220424

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220426